One of the critical and unanswered questions about the value of genomic/genetic testing in relation to the diagnosis and prognosis of prostate cancer is, “What are the currently available tests actually telling us compared to the clinical data?” … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Diagnosis, genetic, genomic, prognosis, risk, test | 2 Comments »
The concept of “minimal residual disease” or MRD and how it affects risk for cancer-specific mortality is a subject of growing importance in the management of many cancers. But it is relatively new to the world of prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: disease, minimal, MRD, prognosis, residual | 3 Comments »
According to a study just published in Cancer Research, a completely new technique referred to as “single cell genomics” may be able to improve the accuracy of diagnosis of prostate cancer based on biopsy tissue. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: cell, dagnosis, genomics, Gleason, grade, prognosis, score, single | 2 Comments »
Our friends at UroToday have just published a perfectly lovely lecture on this topic given by Prof. Lenny Gomella at the recent annual meeting of the Large Urology Group Practice Association (LUGPA). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Diagnosis, genetics, genomics, prognosis, screening, Treatment | 7 Comments »
A relatively brief, current, full-text review article by Loeb and Ross is available on the Medscape web site and discusses the three currently available tests for assessment of genomic risk for men with localized forms of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Decipher, genome, Oncotype, prognosis, PROLARIS, test | 4 Comments »
A new paper by a group of Chinese researchers has suggested that levels of a biochemical called interleukin-35 (IL-35) in blood plasma may offer evidence of the presence of prostate cancer and do so significantly better than PSA levels (particularly for men with PSA levels of between 4 and 10 ng/ml). … READ MORE …
Filed under: Diagnosis, Risk | Tagged: Diagnosis, IL-35, interleukin-35, prognosis, risk | 2 Comments »
